Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 20,367,079	$ 9,748,491
Other current assets	89,488	87,176
Total current assets	20,456,567	9,835,667
Equipment	1,399	0
In-process research and development	5,441,839	5,441,839
Goodwill	629,752	629,752
Total assets	26,529,557	15,907,258
Liabilities and equity
Notes payable, current portion	677,778	877,778
Accounts payable - related party	1,257,600	0
Other accounts payable and accrued expenses	321,725	666,640
Interest payable, current portion	91,944	61,941
Total current liabilities	2,349,047	1,606,359
Notes payable, noncurrent portion, at fair value	4,395,100	4,664,697
Total liabilities	6,744,147	6,271,056
Commitments and contingencies
Equity:
Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 and 413,388 issued and outstanding as of June 30, 2012 and December 31, 2011, respectively, aggregate liquidation value of $0 and $8,267,760 at June 30, 2012 and December 31, 2011, respectively)	0	413
Common stock, $0.001 par value per share (500,000,000 shares authorized, 18,053,995 and 5,061,399 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively)	18,054	5,061
Contingently issuable shares	6	6
Additional paid-in capital	24,001,440	10,472,115
Deficit accumulated in development stage	(13,003,817)	(853,074)
Total TG Therapeutics, Inc. and subsidiaries equity	11,015,683	9,624,521
Noncontrolling interest in subsidiary	8,769,727	11,681
Total equity	19,785,410	9,636,202
Total liabilities and equity	$ 26,529,557	$ 15,907,258